Cortistatin-14 TFA

CAS No. ———

Cortistatin-14 TFA( ——— )

Catalog No. M40629 CAS No. ———

Cortistatin-14 is a neuropeptide have structural similarity to somatostatin-14. It is produced in the cortex and hippocampus of central nervous system.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cortistatin-14 TFA
  • Note
    Research use only, not for human use.
  • Brief Description
    Cortistatin-14 is a neuropeptide have structural similarity to somatostatin-14. It is produced in the cortex and hippocampus of central nervous system.
  • Description
    Cortistatin-14 is a neuropeptide have structural similarity to somatostatin-14. It is produced in the cortex and hippocampus of central nervous system.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    ———
  • Formula Weight
    ———
  • Molecular Formula
    ———
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Revdofilimab

    Revdofilimab (ABBV-368) is a human IgG1 monoclonal antibody that acts as an agonist against OX40, a TNF receptor superfamily member expressed on activated and memory T cell subsets as well as T regulatory cells .

  • γ-Asarone

    γ-Asarone, a phenylpropene, shows strong correlation with the biological activities (anti-oxidative, anti-inflammatory and neurotrophic effects).

  • LY-3475070

    LY-3475070 is a potent and selective CD73 inhibitor with an IC50 of 28 nM, and its use alone or in combination with pembrolizumab is currently being tested in patients with advanced cancer.